KLK3 and prostate cancer: Switching between 5ARIs can substantially affect PSA levels, potentially impacting whether a biopsy is undertaken [14]; this puts additional burden on urologists as they optimize treatment while considering fluctuating PSA results and their impact on prostate cancer diagnosis.